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1. Introduction 
Management of the patient with gender identity disorder involves many different aspects of 
medical care. Transsexualism is a multidimensional phenomenon that requires a 
multidisciplinary approach in both the diagnostic and treatment phases. Endocrinologists 
have to work together with mental health professionals and surgeons to provide full 
counselling, confirm the diagnosis and avoid mistakes or regrets. Hormonal therapy not 
only has a therapeutic role but also an important diagnostic tool.  
Trends in Europe are toward treatment of patients at early age if the diagnosis is 
appropriately established. This may begin with blocking agents that temporarily suppress 
pubertal transformation. Secondary sexual trait suppression allows much more successful 
gender transformation.  
Hormonal therapy is used to suppress secondary sexual characteristic of the biological sex, 
to induce the secondary sex characteristics of the new sex. This therapy should continue 
lifelong[1]. 
2. Masculinizing effect in female to male hormonal therapy 
Endocrinologic masculinization is achieved by the use of testosterone to induce male 
physical characteristics. Testosterone works primarily by direct stimulation of receptors in 
target tissues. It elevates serum testosterone level to a male reference range rather than a 
decrease in serum estradiol[2]. Testosterone also has antigonadotropic action in high 
doses.  
Rapidity and degree of change from testosterone therapy depends on the agents used, 
dosage, and the patient's responsiveness to endocrine therapy. Typically, within the first 
1-3 months patients experience oilier skin and acne, increased libido, increased muscle 
mass and upper body strength, and redistribution of the fat to a more masculine 
pattern[3, 12]. 
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The voice changes to crack and deepen within the first 3-6 months, but it can take a year or 
more for the voice pitch to fully drop [13]. 
In 75% FTMs testosterone will cause voice pitch to drop to a level sufficient for passability as 
male even on the telephone [4]. 
The clitoral enlargement begins within the first few months of testosterone initiation and 
typically plateaus within the first year [14, 15]. The degree of enlargement is variable with 
studies reporting a range of 3.5 – 6 cm maximal when stretched [14, 15, 16]. Clitoral growth 
dose not appear to be enhanced by topical application of testosterone to the clitoris. 
Long-term testosterone use causes vaginal and cervical atrophy [3, 17], with decreased 
vaginal secretion and difficult penetration [12]. 
In most cases, menses stop within 1 – 6 months [5-8, 14-16, 18, 19]. If after three months 
menses have not stopped, the dosage of testosterone may be increased until serum free 
testosterone is within upper quartile of the normal male range or menses stop. Despite 
endometrial atrophy, cessation of menses, and reduced fertility there is evidence of 
ovulation even after several years of testosterone administration [17]. 
There is gradual increased growth, coarseness, and thickness of hair on the torso and 
extremities in the first year [3, 4, 6, 7, 16]. Facial hair increases more slowly, typically taking 
1 - 4 years to reach full growth. Some patients experience male pattern baldness during this 
later stage of masculinization [4, 6-8, 11, 20]. 
Voice change, facial hair growth and male pattern baldness are not reversible, which other 
changes are reversible if hormone is stopped. Clitoral growth and sterility may or may not 
reversible(Table 1). 
Effect 
Onset 
(months) 
Maximum 
(yr) 
Skin oiliness/acne 1-6 1-2 
Facial/body hair growth 6-12 4-5 
Scalp hair loss 6-12 
 
Increased muscle mass/strength 6-12 2-5 
Fat redistribution 1-6 2-5 
Cessation of menses 2-6 
 
Clitoral enlargement 3-6 1-2 
Vaginal atrophy 3-6 1-2 
Deepening of voice 6-12 1-2 
Table 1. Masculinizing effects in FTM transsexual persons 
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3. Recommended masculinizing male hormone regimen 
Most commonly used preparations are injectable testoterone esters (Jenatestoterone®) 
administration intramuscularly in dose 200 - 250 mg every two weeks [21]. Sometimes, 
masculinization effect is low or when patient wants to bring rapid masculinization 
testosterone esters administrated intramuscularly in dose 200 - 250 mg every week. Serum 
testosterone level is checked every 3 months for first year and then 1 - 2 times per year 
afterward for appropriate signs of feminization and for development of adverse reaction. 
Serum testosterone level should be maintained <55 ng/dl.  
At least 12 months of treatment of testosterone can achieve the masculinization. After 
oophorectomy or achievement of masculinization, administration of testosterone will be 
reduced to every three or four weeks. Serum testosterone level should be needed to keep 
within the middle or lower-middle end of the male range. Long acting testosterone 
undecanoate 1000 mg is available and injections may leave a space at 10 - 12 weeks [22], but 
masculinizing effect is not certain. Transdermal gel and transdermal patch can be used and 
also provide good, steady-state testosterone level. AndroGel® is applied 5 - 10 g qd. 
Androderm® patch is also applied 5 – 10 g daily [23]. 
To preserve bone density following oophorectomy, testosterone supplementation should be 
maintained throughout life, and calcium and vitamine D supplementation is recommended 
[23]. 
4. Recommended monitoring following initial testosterone therapy 
At minimum, patients should be seen every month after initiating treatment or while 
adjusting medication dosages, then every 3 months for the first year, then every six months 
thereafter. The primary focus of monitoring cross-sex hormone use is to assess the degree of 
masculinization and the possible presence of adverse effects of medication. However, as 
with monitoring of any long-term medication, monitoring should take place in the context 
of comprehensive care of all health concerns. 
Mascullinization takes place gradually over a period of years. Observed changes to male 
pattern hair growth and voice should be noted, and the patient should be asked about 
changes to menstrual pattern, mood, clitoral growth, libido, and sexual function. Other 
changes should also be noted. To avoid a supraphysiological dose of testosterone, serum 
free testosterone should be checked 2 - 4 weeks after the starting dose or after a dose 
adjustment, and every 6 - 12 months thereafter. 
All exams should include assessment of weight, cardiovascular risk, diabetes risk, and blood 
pressure. There are case reports of destabilization of bipolar disorder, schizophrenia, and 
schizoaffective disorder in non-transgender men with the use of testosterone. Mental health 
should be monitored carefully in FTMs with these condition for the duration of testosterone 
therapy. 
At minimum, laboratory tests should include fasting blood glucose, hemoglobin, lipid 
profile, and liver enzymes. The fasting blood glucose should be checked 3 and 6 months 
after starting testosterone or after a dose adjustment, then annually increase frequency and 
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monitor A1c if elevated lipids, significant weight gain, elevated fasting glucose levels, 
personal history of glucose intolerance, or family history of diabetes. Hemoglobin should be 
checked 3 and 6 months after starting testosterone or after a dose adjustment, then annually. 
Lipid profile is needed to evaluate 3 and 6 months after starting testosterone or after a dose 
adjustment, then annually. Liver enzymes also should be checked 3 and 6 months after 
starting testosterone or after dose increase, then annually. 
5. Effect of the long-term treatment of testosterone on health 
The goal of treatment in the FTM is to induce virilization, deepening of the voice, 
production of male-pattern body hair growth, and physical contours, and cessation of 
menses. 
The principal hormonal treatment used to accomplish these goals is testosterone 
preparation. After reassignment surgery, which includes oophorectomy and hysterectomy, 
hormonal therapy must be continued. It is reasonable to assume that the principles of 
treatment are very similar to a person without their own gonadal hormone secretion. 
An unresolved question is whether in the long term all functions of sex steroids of a subject 
are adequately covered by cross-sex hormones and whether the administration of cross-sex 
hormones is appropriate safe. Nearly all hormone related biochemical processes can be sex 
reversed by administration of cross-sex hormone.  
The complication of cross-sex hormone therapy is underreported. Although complications 
occurring in the long term are seen in general practice, and these complication are only 
occasionally reported in the scientific literature. 
Polycythemia and erythrocytosis were observed in testosterone administration as a rare 
complication[24, 25]. Relative contraindication (e.g. persons who smoke, have diabetes, have 
liver diseases,etc) to therapy have been published and should have an in-depth discussion 
with their physician to balance the risk and benefit of therapy[26]. The worrisome 
complication of water and sodium retention increased body weight, decreased insulin 
sensitivity, obstructive sleep apnea, acne, poor lipid profile, and an increase in hematocrit 
have raised the concern for cardiac and thromboembolytic events. 
Cerebral vascular accidents have been reported for individuals with supraphysiological 
level of testosterone[27, 28]. Polycystic ovarian disease is a risk factor for endometrial 
cancer[27] As the association between polycystic ovarian disease and risk of endometrial 
and ovarian malignancy are not entirely clear and seen in greater numbers in transsexual 
people before androgen therapy than in the general population[28, 29]. Mild endometrial 
hyperplasia has been appreciated on removal of the uterus[30]. A case reported in 2 
transsexuals with ovarian cancer[31]. Recommendation for hysterectomy and bilatel 
salpingoooporectomy, generally carried out around 15 months after the start of testosterore 
treatment in the male to female transsexuals, has yet to be fully justified, at least on the 
grounds of enhanced risk of malignancy. 
Total hysterectomy after 2 years of testosterone therapy, followed by 50% reduction in 
hormone man be a way to avoid these risks[32, 33](Table 2). 
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1. Water and sodium retention 
2. Increased erythropoiesis 
3. Decreased carbohydrate tolerance 
4. Decreased serum high-density lipoprotein (HDL) cholesterol 
5. Elevated liver enzymes 
6. Weight increase >10% 
7. Emotional or psychiatric problems 
8. Sleep apnea 
9. Acne 
10. Endometrial hyperplasia 
11. Aggression and hypersexuality 
12. Decreased insulin sensitivity 
13. Increased IGF 
14. Decreased bone mineral density after gonadectomy 
15. Ovarian cancer 
Table 2. Side Effects of Androgen Therapy in F-T-M Transsexuals 
6. The effect of the testosterone on uterus and ovary 
Human endometrium is a steroid-hormone-dependent tissue whose growth and remodeling 
respond to estrogen and progesterone secreted from ovary. Increasing circulating estradiol 
(E2) levels, a consequence of ovarian follicular growth named as ˄follicular˅ phase of the 
cycle, promote endometrial cellular proliferation and tissue thickness, from approximately 2 
mm after the postmenstrual repair phase, to 10–12 mm in the periovulatory period. [34] 
Although myometrial tissues are also influenced by estrogen stimulation for the growth and 
remodeling, they do not show such dramatic change as much as endometrium.  
Testosterone treatments to the female to male transsexuals are a usual method to induce 
masculinization. Testosterone is one of the potent circulating androgens which are produced 
from testis and ovary. Ovary and adrenal gland in women produce not only female sex 
hormones and mineralcorticoid, but also androgens, such as testosterone, androstenedione 
and dehydroepiandrostenedione or its sulfate. Several studies have shown that high plasma 
androgen levels are associated with adverse reproductive outcome, including infertility and 
increased incidence of miscarriage.[35, 36] Those clinical features imply that androgens have 
a potency to affect the endometrial cellular function and promote histological changes. 
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Polycystic ovary syndrome (PCOS), which is characterized by high circulating testosterone 
and androstenedione level, expresses different endometrial pattern, such as endometrial 
hyperplasia or cancer, compared to women with normal androgen level.[37] Those 
pathologic changes in PCOS patients are attributed to estrogen stimulation to the 
endometrium, which is aromatized from circulating androgens. Hyperandrogenic 
symptoms like acne or hirsutism are found in some PCOS patients.  
However, it is rarely reported what effect on the uterus would be observed after long term 
exogenous testosterone treatment among FTM patients. Although it is easily acceptable that 
there are no definite gross changes of uterus and ovary, interesting histological features are 
expressed in a few articles. In 1986, Miller et al. reported histologic characteristics of uterus 
extirpated from FTMs. In the study, severe atrophied uterine cervix was found and variable 
degrees of atrophic change of endometrium were observed as well.[38] Such changes have 
been also observed in our previous histologic study on the extirpated uterus from 16 
FTMs.(Fig.1, Fig.2) These changes are comparable with proliferative change of endometrium 
in PCOS. This means that androgen action on endometrium in FTMs is much higher than 
that of PCOS patients. Meanwhile, we also found that ovarian histologic changes in FTMs 
were polycystic appearance similar to those of PCOS.[39](Fig. 3) It is thought that the 
polycystic change of ovary might be due to multiple follicle recruitment action caused by 
androgen, which is thought to be the pathophysiologic theory about PCOS. 
Finally, it is concluded that the histolgic changes of endometrium and ovary are atrophic 
and polycystic appearance according to the duration of testosterone treatments. Molecular 
mechanisms on those changes would be clarified in the future.   
 
Fig. 1. Atrophied epithelium of exocervix (H-E, X400) (Kor J Fertil Steril 2005;32:325-330) 
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Fig. 2. Atrophy of endometrium (H-E, ×200). (Kor J Fertil Steril 2005;32:325-330) 
 
Fig. 3. Multiple cystic follicles in the ovarian cortex (H-E, X10) (Kor J Fertil Steril 2005;32:325-
330) 
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7. Conclusions 
The use of hormonal therapy in transsexualism is associated with appropriate physical 
change. Side effects in carefully monitored patients are usually few but are more likely to 
cause serious complications when therapy is too aggressive. This is particularly true in the 
FTM transsexual patients who are likely candidates for complications of dyslipoproteinemia 
which include premature atherogenesis, diabetes mellitus, hypertension, increased insulin 
resistance, and obesity. Investigators propose that initial treatment with androgen therapy 
which must be supraphysiological to suppress gonadotropins and virilize the patient should 
be kept to maximum of no more than 2 years. Following sex reassignment surgery, the 
dosage should be reduced by half in most patients. 
It is likely to reduce not only the duration of large dosage androgen therapy but also the 
potential risk of endometrial hyperplasia and uterine carcinoma. The role of the concerned 
physician is to be fully aware of potential risk of this therapy so as to adjust treatment and 
minimize potential complications. 
8. References 
[1] Kaufman, D., & Maasdam, J. V. (2006). Surgery for gender identity disorder, Plastic 
surgery, 2nd ed. Philadelphia, PA: Sounders., 1305-1316. 
[2] Moore, E., Wisniewski, A., & Dobs, A. (2003). Endocrine treatment of transsexual people: 
a review of treatment regimens, outcomes, and adverse effects. Journal of Clinical 
Endocrinology & Metabolism, 88, 3467-3473.  
[3] Schlatterer, K., von Werder, K., & Stalla, G. K. (1996). Multistep treatment concept of 
transsexual patients. Experimental and Clinical Endocrinology and Diabetes, 104, 
413-9.  
[4] Kirk, S., & Rothblatt, M. (1995). Medical, legal and workplace issues for the transsexual. 
Watertown, MA: Together Lifeworks.  
[5] Steinbeck, A. (1997). Hormonal medication for transsexuals. Venereology: 
Interdisciplinary, International Journal of Sexual Health, 10, 175-177.  
[6] Tangpricha, V., Ducharme, S. H., Barber, T. W., & Chipkin, S. R. (2003). Endocrinologic 
treatment of gender identity disorders. Endocrine Practice, 9, 12-21. 
[7] Bromham, D. & Pearson, R. (1996). The pharmacological treatment of transsexuals. 
British Journal of Sexual Medicine, 23(5) [no page numbers in file copy].  
[8] Flaherty, C., Franicevich, J., Freeman, M., Klein, P., Kohler, L., Lusardi, C., Martinez, L., 
Monihan, M., Vormohr, J., & Zevin, B. (2001). Protocols for hormonal reassignment 
of gender. San Francisco: San Francisco Department of Public Health. Retrieved 
January 1, 2005, from http://www.dph.sf.ca.us/chn/HlthCtrs/HlthCtrDocs/ 
TransGendprotocols.pdf  
[9] Elbers, J. M. H., Asscheman, H., Seidell, J. C., & Gooren, L. J. G. (1999). Effects of sex 
steroid hormones on regional fat depots as assessed by magnetic resonance 
imaging in transsexuals. American Journal of Physiology, 276, E317-E325. 
[10] Slabbekoorn, D., Van Goozen, S. H. M., Gooren, L. J. G., & Cohen-Kettenis, P. T. (2001). 
Effects of cross-sex hormone treatment on emotionality in transsexuals. 
International Journal of Transgenderism, 5. Retrieved January 1, 2005, from 
http://www.symposion.com/ijt/ijtvo05no03_02.htm 
www.intechopen.com
Know-How of the Hormonal Therapy and the Effect  
of the Male Hormone on Uterus in the Female to Male Transsexuals 343 
[11] Dimensions (2003). Informed consent for testostorone therapy for female-to-male 
transition. San Francisco, CA: Castro-Mission Health Center, San Francisco 
Department of Public Health. Retrieved January 1, 2005, from http://tghealth-
critiques.tripod.com /consen2.htm 
[12] The Gender Centre Inc. (2001). Testosterone hormone information II. Sydney, Australia: 
The Gender Centre Inc. Retrieved January 1, 2005, from http://www.gendercentre. 
org.au/testosterone_2.htm 
[13] Van Borsel, J., De Cuypere, G., Rubens, R., & Destaerke, B. (2000). Voice problems in 
female-to-male transsexuals. International Journal of Language & Communication 
Disorders, 35, 427-442.  
[14] Gooren, L. J. G. (n.d.). Transsexualism: Introduction and general aspects of treatment. 
Retrieved January 1, 2005, from http://www.xs4all.nl/~txtbreed/gender/ 
gooren.html 
[15] Meyer, W. J., III, Webb, A., Stuart, C. A., Finkelstein, J. W., Lawrence, B., & Walker, P. 
A. (1986). Physical and hormonal evaluation of transsexual patients: a longitudinal 
study. Archives of Sexual Behavior, 15, 121-138.  
[16] Meyer, W. J., III, Finkelstein, J. W., Stuart, C. A., Webb, A., Smith, E. R., Payer, A. F., & 
Walker, P. A. (1981). Physical and hormonal evaluation of transsexual patients 
during hormonal therapy. Archives of Sexual Behavior, 10, 347-56.  
[17] Miller, N., Bedard, Y. C., Cooter, N. B., & Shaul, D. L. (1986). Histological changes in the 
genital tract in transsexual women following androgen therapy. Histopathology, 
10, 661-669.  
[18] Futterweit, W. (1998). Endocrine therapy of transsexualism and potential complications 
of long-term treatment. Archives of Sexual Behavior, 27, 209-226.  
[19] Israel, G. E, & Tarver, D. E. I. (1997). Transgender care: Recommended guidelines, 
practical information, and personal accounts. Philadephia, PA: Temple University 
Press.  
[20] Feldman, J. & Bockting, W. O. (2003). Transgender health. Minnesota Medicine, 86, 25-
32.  
[21] Louis, J. G., Erik J. G., & Mathijs, C. B. (2008). Long-Term Treatment of Transsexuals 
with Cross-Sex Hormones: Extensive Personal Experience. J Clin Endocrinol Metab, 
93, 19-25. 
[22] Louis, G. (2005). Hormone Treatment of the Adult Transsexual Patient. Horm Res, 64(2), 
31-36 
[23] Vancouver Coastal Health, Transcend Transgender Support & Education Society, and 
the Canadian Rainbow Health Coalition. (2006). Endocrine therapy for transgender 
adults in British Columbia: Suggested guidelines. from http://transhealth.vch.ca 
[24] Wilson, J., & Griffin, J. (1980). The use and misuse of androgens. Metabolism, 29, 1278–
1295. 
[25] Ammus, S. (1989) The role of androgens in the treatment of hematologic disorders. Adv 
Intern Med, 34, 191–208 
[26] Nagelberg, S., Laue, L., Loriaux, L., Liu, L., & Sherins, R. (1986) Cerebrovascular 
accident associated with testosterone therapy in a 21-year-old hypogonadal man. N 
Engl J Med, 314, 649–650 
[27] Futterweit, W. (1984) Clinical features of polycystic ovarian disease. In: Polycystic 
ovarian disease. New York: Springer-Verlag; 83–95  
www.intechopen.com
 Hysterectomy 344 
[28] Futterweit, W., Weiss, R., & Fagerstrom. (1986) Endocrine evaluation of forty female-to-
male transsexual people: increased frequency of polycystic ovarian disease in 
female transsexualism. Arch Sex Behav, 15, 69–78. 
[29] Balen. A., Schachter. M., Montgomery, D., Reid, R., & Jacobs, H. (1993) Polycystic 
ovaries are a common finding in untreated female to male transsexual people. Clin 
Endocrinol (Oxf) 38, 325–329. 
[30] Futterweit. W., & Deligdisch, L. (1986) Histopathological effects of exogenously 
administered testosterone in 19 female to male transsexual people. J Clin 
Endocrinol Metab, 62, 16–21. 
[31] Hage, J., Dekker, J., Karim. R., Verheijen, R., & Bloemena, Em. (2000) Ovarian cancer in 
female-to-male transsexual people: report of two cases. Gynecol Oncology, 76, 413–
415.  
[32] Michel, A., Mormont, C., & Legros, J. (2001). A psycho-endocrinological overview of 
transsexualism. Eur J Endocrinol, 145, 365–376. 
[33] Leiter, E., Futterweit, W,, & Brown, G. (1993). In: Webster G, Kirby R, King L, 
Goldwasser B, eds. Reconstructive urology. Boston: Blackwell Scientific 
Publications; 23, 921–932 
[34] Giudice LC. Elucidating endometrial function in the post-genomic era. Human 
Reproduction Update 2003;9: 223–235.  
[35] Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who 
suffer recurrent miscarriage and their correlation with markers of endometrial 
function. Fertil Steril 1998;69:682–90. 
[36] Tulppala M, Stenman UH, Cacciatore B, Ylikorkala O. Polycystic ovaries and levels of 
gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 
women. Br J Obstet Gynaecol 1993;100:348 –52. 
[37] Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in 
polycystic ovary syndrome. Obstetrics and Gynecology 2001; 98: 325–331. 
[38] Miller N, Bedard YC, Cooter NB, Shaul DL. Histological changes in the genital tract in 
transsexual women following androgen therapy. Histopathology 1986; 10: 661-9. 
[39] Byun JC, Kwak BG, Shin JH, Cha MS, Han MS, Rha SH, Kim SK. The Histologic 
Features of the Uterus and Adnexa Extirpated from Gender Identity Disorder 
Patients with Depot Androgen Injection. Kor J Fertil Steril 2005;32:325-330. 
www.intechopen.com
Hysterectomy
Edited by Dr. Ayman Al-Hendy
ISBN 978-953-51-0434-6
Hard cover, 426 pages
Publisher InTech
Published online 20, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is intended for the general and family practitioners, as well as for gynecologists, specialists in
gynecological surgery, general surgeons, urologists and all other surgical specialists that perform procedures
in or around the female pelvis, in addition to intensives and all other specialities and health care professionals
who care for women before, during or after hysterectomy. The aim of this book is to review the recent
achievements of the research community regarding the field of gynecologic surgery and hysterectomy as well
as highlight future directions and where this field is heading. While no single volume can adequately cover the
diversity of issues and facets in relation to such a common and important procedure such as hysterectomy,
this book will attempt to address the pivotal topics especially in regards to safety, risk management as well as
pre- and post-operative care.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Seok Kwun Kim and Myoungseok Han (2012). Know-How of the Hormonal Therapy and the Effect of the Male
Hormone on Uterus in the Female to Male Transsexuals, Hysterectomy, Dr. Ayman Al-Hendy (Ed.), ISBN: 978-
953-51-0434-6, InTech, Available from: http://www.intechopen.com/books/hysterectomy/know-how-of-the-
hormonal-therapy-and-the-effect-of-the-male-hormone-on-uterus-in-the-female-to-male-
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
